Downloads

Data Insights: Top referral specialties and medications driving 340B savings

As the healthcare industry becomes increasingly competitive, understanding how to maximize savings and increase revenue is more important than ever. This insightful report reveals the top-performing specialties and medications that are generating significant 340B savings for healthcare organizations.

Our 340B team has conducted an in-depth analysis of over two calendar years of data across more than 230 covered entity sites to reveal which drugs, therapeutic classes, and medical specialties are generating the biggest savings through referral prescriptions within the contract pharmacy domain.

Download our research report today!

Related Resources

African American male pharmacist using digital tablet during inventory in pharmacy.

Reimbursement

The Three Most Common Ways 340B Referral Savings are Missed

Author: Donald Holladay, PharmD, 340B ACE Referral prescriptions can be a critical source of 340B opportunity for covered entities (CEs) in their mission to “…stretch federal r...

Learn more

Reporting and Compliance

3 Key Compliance Components for 340B Covered Entities

Ensure readiness for an HRSA audit with these three steps and protect your 340B savings.

Learn more

Revenue Integrity

Interpreting the HRSA 340B Drug Pricing Program

Although its benefits are great, the 340B Drug Pricing Program leaves a lot up to interpretation by participating covered entities when it comes to compliance – especially with "referral prescriptions." Referral prescriptions – or prescriptions resulting from referrals to outside specialists – have long been a point of confusion under the 340B program. Can 340B participating organizations capture these prescriptions? If so, how?

Learn more